Entrada Therapeutics
Aims to treat devastating diseases through the intracellular delivery of biologics.
Launch date
Employees
Market cap
AUD854m
Enterprise valuation
AUD227m (Public information from Sep 2024)
Share price
$14.68 TRDA
Boston Massachusetts (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | 129m | 176m | 39.9m | 38.8m |
| % growth | - | - | - | - | 36 % | (77 %) | (3 %) |
| EBITDA | (26.3m) | (51.1m) | (97.2m) | (<1m) | 11.6m | (142m) | (152m) |
| % EBITDA margin | - | - | - | - | 7 % | (355 %) | (391 %) |
| Profit | (26.5m) | (51.2m) | (94.6m) | (6.7m) | 17.1m | (156m) | (186m) |
| % profit margin | - | - | - | (5 %) | 10 % | (392 %) | (480 %) |
| EV / revenue | - | - | - | 3.9x | 2.3x | 11.4x | 15.9x |
| EV / EBITDA | - | -4.8x | -3.9x | -1567.0x | 35.5x | -3.2x | -4.1x |
| R&D budget | 21.1m | 35.9m | 66.6m | 99.9m | - | - | - |
| R&D % of revenue | - | - | - | 77 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $600k | Seed | |
* | $59.0m | Series A | |
$116m | Series B | ||
| N/A | $182m Valuation: $598m -22.7x EV/LTM EBITDA | IPO | |
* | $26.0m | Post IPO Equity | |
* | N/A | $100m | Post IPO Equity |
| Total Funding | AUD271m | ||
Recent News about Entrada Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.